Mirova US LLC Has $273.42 Million Stake in Danaher Co. (NYSE:DHR)

Mirova US LLC decreased its holdings in Danaher Co. (NYSE:DHR) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,181,875 shares of the conglomerate’s stock after selling 5,496 shares during the period. Danaher comprises 4.1% of Mirova US LLC’s portfolio, making the stock its 11th largest holding. Mirova US LLC owned about 0.16% of Danaher worth $273,415,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in DHR. Moneta Group Investment Advisors LLC grew its stake in shares of Danaher by 96,490.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock valued at $6,180,839,000 after buying an additional 23,262,904 shares in the last quarter. Norges Bank bought a new stake in shares of Danaher in the 4th quarter valued at approximately $2,057,164,000. Wellington Management Group LLP boosted its position in Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares during the period. Allen Investment Management LLC boosted its position in Danaher by 1,440.7% during the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after purchasing an additional 1,028,976 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC bought a new stake in Danaher during the third quarter worth approximately $178,850,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR traded up $0.68 during trading hours on Wednesday, reaching $240.34. The stock had a trading volume of 3,225,524 shares, compared to its average volume of 2,272,667. The business’s fifty day moving average is $249.42 and its two-hundred day moving average is $229.79. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The company has a market cap of $177.98 billion, a price-to-earnings ratio of 37.61, a PEG ratio of 3.64 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. Danaher’s revenue was down 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.87 earnings per share. As a group, research analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 16.90%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DHR shares. Barclays upped their target price on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. KeyCorp upped their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Royal Bank of Canada increased their price objective on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Citigroup increased their price objective on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Raymond James increased their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $267.43.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Danaher news, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock worth $8,265,802 over the last three months. 10.90% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.